EUR 25 million series A financing raised by CENTOGENE

CENTOGENE AG recently announced its 25 million EUR Series A financing round led by TVM Capital Life Science in collaboration with DPE Deutsche Private Equity, Careventures and CIC Capital. This will be used to accelerate the company’s further growth and expansion plans in the business segments of worldwide Genetic Testing, Pharmaceutical Collaborations and Big Data-Solutions.

The funding will also enable the company to broaden its portfolio of biomarkers, companion diagnostics and tools for oncogenetics.

Prof. Arndt Rolfs, MD, CEO and Founder of CENTOGENE AG said, "There is a large unmet need for early and easy diagnosis and treatment of rare hereditary diseases.  This creates a tremendous market opportunity for us. We are very pleased to have this international investor consortium on board who not only shares our vision for future growth to put innovation into precision medicine, but also provides the necessary access to an international network to realize our vision on a real global basis."

Dr. Hubert Birner, Managing Partner, TVM Capital Life Science said,  "We are very glad to support a highly innovative company, already a world leader in its field, on its journey towards innovating modern medicine, genetic diagnostics and the treatment of genetic diseases. CENTOGENE, headquartered in Rostock, is the second investment in the history of TVM Capital Life Science residing in the federal state of Mecklenburg-Western Pomerania. That proves that Germany’s vibrant life sciences and biotech industry is widespread across the country."

Guido Prehn, Partner at DPE Deutsche Private Equity said, "CENTOGENE’s genetics database coupled with its in-depth clinical knowledge positions the company perfectly to continue on its growth trajectory. It uniquely addresses the challenges of the pharmaceutical industry in a market that develops towards evidence-based and personalized medicine."

Eric Souetre, Managing Partner of Careventures said, "We are proud to support one of the world leaders in genetic testing and biomarkers discovery. With an exceptional scientific and development team, we are confident that CENTOGENE will strengthen its presence over the five continents."

Sébastien Neiss, Director in charge of Germany for CIC Capital said, "We are very happy that the investment in CENTOGENE, a company with strong fundamentals, is the first implementation of our new international strategy in Germany aiming at investing in growing midsize companies alongside renowned investors."